[{"id":"8339e713-54fb-436e-b405-f5f09796300c","acronym":"QLS31904-101","url":"https://clinicaltrials.gov/study/NCT05461287","created_at":"2022-07-18T14:01:29.153Z","updated_at":"2024-07-02T16:36:00.599Z","phase":"Phase 1","brief_title":"Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05461287 - QLS31904-101","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e QLS31904"],"overall_status":"Recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/25/2024","primary_completion_date":" 09/25/2024","study_txt":" Completion: 05/25/2025","study_completion_date":" 05/25/2025","last_update_posted":"2022-11-10"}]